Clinical Trial

Antibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine (VLA1553)

Name: Antibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine (VLA1553) — clinical trial record (NCT04838444)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Active, Not Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

In this open-label Phase 3b, single arm trial, persistence of antibodies and long term safety will be evaluated in up to 375 participants rolled over from trial VLA1553-301 (NCT number: NCT04546724).

Protocol Amendment History 1 change

critical Primary endpoint(s) modified 2026-07-19

Trial Details

NCT Number	NCT04838444
Lead Sponsor	Valneva Austria GmbH
Conditions	Chikungunya Virus Infection
Enrollment	363 participants
Start Date	2021-04-02
Primary Completion	2023-03-03 (estimated)
Study Completion	2031-05 (estimated)
Updated on ClinicalTrials.gov	2026-07-09